Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (397)	12/7/1998 5:04:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1494

The neurontin results are comparable to those for memantine and neurontin appears to be almost as safe. the occurence of adverse side effects, particularly diziness and somnolence are higher than seen for memantine, but are not real bad. Neurontin, in general reduced pain ratings by about 30%, the same range as memantine. But, the patients still indicated that they had significant pain. 4.2 on a 10 points scale. So, there is room for better or additional treatments. The mechanism of action on neurontin is unknown. But, it doesnt appear to work via the NMDA receptor as does memantine. This means that they have different modes of action and they may be able to be used together to further reduce the pain. John de C